| Intraperitoneal therapy in ovarian cancer: time's up |
| RF Ozols |
|
JCO Feb 1 1991: 197–199.
[PDF]
|
 |
| Making cocktails versus making soup |
| R Gelman and D Neuberg |
|
JCO Feb 1 1991: 200–203.
[PDF]
|
|
|
Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma |
| |
M Markman, T Hakes, B Reichman, W Hoskins, S Rubin, W Jones, L Almadrones, EL Yordan, Jr, J Eriksson, and JL Lewis, Jr |
| |
JCO Feb 1 1991: 204–210.
[Abstract]
[PDF]
|
|
|
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs |
| |
B Coiffier, C Gisselbrecht, JM Vose, H Tilly, R Herbrecht, A Bosly, and JO Armitage |
| |
JCO Feb 1 1991: 211–219.
[Abstract]
[PDF]
|
|
|
Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B |
| |
PJ Hoskins, V Ng, JJ Spinelli, P Klimo, and JM Connors |
| |
JCO Feb 1 1991: 220–226.
[Abstract]
[PDF]
|
|
|
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment |
| |
DL Longo, A Russo, PL Duffey, SM Hubbard, E Glatstein, JB Hill, ES Jaffe, RC Young, and VT DeVita, Jr |
| |
JCO Feb 1 1991: 227–235.
[Abstract]
[PDF]
|
|
|
Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse |
| |
LE Robertson, JR Redman, JJ Butler, BM Osborne, WS Velasquez, P McLaughlin, F Swan, MA Rodriguez, FB Hagemeister, and LM Fuller |
| |
JCO Feb 1 1991: 236–242.
[Abstract]
[PDF]
|
|
|
Pentostatin induces durable remissions in hairy cell leukemia |
| |
PA Cassileth, B Cheuvart, AS Spiers, DP Harrington, FJ Cummings, RS Neiman, JM Bennett, and MJ O'Connell |
| |
JCO Feb 1 1991: 243–246.
[Abstract]
[PDF]
|
|
|
A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study |
| |
CP Steuber, C Civin, J Krischer, S Culbert, A Ragab, FB Ruymann, Y Ravindranath, B Leventhal, R Wilkinson, and TJ Vietti |
| |
JCO Feb 1 1991: 247–258.
[Abstract]
[PDF]
|
|
|
Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma |
| |
ES Kleinerman, JS Snyder, and N Jaffe |
| |
JCO Feb 1 1991: 259–267.
[Abstract]
[PDF]
|
|
|
Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group |
| |
J Raine, A Bowman, K Wallendszus, and J Pritchard |
| |
JCO Feb 1 1991: 268–273.
[Abstract]
[PDF]
|
|
|
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma |
| |
BH Kushner, RJ O'Reilly, LR Mandell, SC Gulati, M LaQuaglia, and NK Cheung |
| |
JCO Feb 1 1991: 274–279.
[Abstract]
[PDF]
|
|
|
Intensive weekly chemotherapy for good-prognosis patients with small- cell lung cancer |
| |
DW Miles, HM Earl, RL Souhami, PG Harper, R Rudd, CM Ash, L James, CW Trask, JS Tobias, and SG Spiro |
| |
JCO Feb 1 1991: 280–285.
[Abstract]
[PDF]
|
|
|
Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer |
| |
T Saphner, DC Tormey, and R Gray |
| |
JCO Feb 1 1991: 286–294.
[Abstract]
[PDF]
|
|
|
Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial |
| |
T Habeshaw, J Paul, R Jones, S Stallard, M Stewart, SB Kaye, M Soukop, RP Symonds, NS Reed, and EM Rankin |
| |
JCO Feb 1 1991: 295–304.
[Abstract]
[PDF]
|
|
|
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group |
| |
|
| |
JCO Feb 1 1991: 305–312.
[Abstract]
[PDF]
|
|
|
Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial |
| |
VW Rusch, R Figlin, D Godwin, and S Piantadosi |
| |
JCO Feb 1 1991: 313–319.
[Abstract]
[PDF]
|
|
|
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support |
| |
AD Elias, LJ Ayash, JP Eder, C Wheeler, J Deary, L Weissman, S Schryber, M Hunt, J Critchlow, and L Schnipper |
| |
JCO Feb 1 1991: 320–327.
[Abstract]
[PDF]
|
|
|
Sex or survival: trade-offs between quality and quantity of life |
| |
PA Singer, ES Tasch, C Stocking, S Rubin, M Siegler, and R Weichselbaum |
| |
JCO Feb 1 1991: 328–334.
[Abstract]
[PDF]
|
|
|
Developing a postgraduate medical oncology training program in Taipei, Taiwan, Republic of China |
| |
PP Carbone |
| |
JCO Feb 1 1991: 335–338.
[Abstract]
[PDF]
|
|
|
The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma |
| |
RM Meyer, WM Hryniuk, and MD Goodyear |
| |
JCO Feb 1 1991: 339–347.
[Abstract]
[PDF]
|
|
|
When is a prognostic factor useful? A guide for the perplexed |
| |
MN Levine, GP Browman, M Gent, R Roberts, and M Goodyear |
| |
JCO Feb 1 1991: 348–356.
[Abstract]
[PDF]
|
|
| Prognostic importance of subdividing clinically staged IIIa and IIIb patients with non-small-cell lung cancer |
| PD Bonomi, M Gale, LP Faber, and S Reddy |
|
JCO Feb 1 1991: 357–359.
[PDF]
|
|
| CA125 and malignant lymphomas |
| C Sebban, Y Lasne, V Berenguer, E Archimbaud, Y Devaux, and JJ Viala |
|
JCO Feb 1 1991: 359–360.
[PDF]
|
|
